DE
  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Medac at the EBMT 2019

    Innovative conditioning therapy for MDS and AML

    During the medac satellite symposium at this year’s 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Prof. Franco Locatelli, from Rome in Italy stated that there is a great need for conditioning treatments that simultaneously offer the maximum antileukaemic effects and reduced toxicity. An innovative treatment option from medac is about to be granted marketing authorisation in Europe.1

     


    1medac press release from 14.12.2018: „New conditioning therapy by medac about to receive European approval“

    Nach oben